{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aspirin+100mg", "query": { "intervention": "Aspirin 100mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 16, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aspirin+100mg&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-16T15:27:46.435Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05625347", "title": "Study to Compare the Pharmacokinetics and Pharmacodynamics of ASA Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Adult Subjects With Obstructive or Restrictive Pulmonary Function", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Obstructive Pulmonary Function", "Restrictive Pulmonary Function" ], "interventions": [ { "name": "single dose (100 mg) of ASA", "type": "DRUG" }, { "name": "single dose (162 mg) of non-enteric-coated chewable aspirin tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vectura, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 4, "start_date": "2023-03-11", "completion_date": "2023-06-30", "has_results": false, "last_update_posted_date": "2024-03-22", "last_synced_at": "2026-09-16T15:27:46.435Z", "location_count": 4, "location_summary": "Orlando, Florida • Winter Park, Florida • Baltimore, Maryland + 1 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Winter Park", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Berlin", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05625347" }, { "nct_id": "NCT01968798", "title": "ASPREE Cancer Endpoints Study", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Aspirin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hennepin Healthcare Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 14500, "start_date": "2013-09", "completion_date": "2024-04", "has_results": false, "last_update_posted_date": "2021-04-05", "last_synced_at": "2026-09-16T15:27:46.435Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Palo Alto, California • Washington D.C., District of Columbia + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01968798" }, { "nct_id": "NCT01082874", "title": "PeriOperative ISchemic Evaluation-2 Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cardiovascular Disease" ], "interventions": [ { "name": "Active Clonidine", "type": "DRUG" }, { "name": "Placebo Clonidine", "type": "DRUG" }, { "name": "Active ASA", "type": "DRUG" }, { "name": "Placebo ASA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hamilton Health Sciences Corporation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": null, "sex": "ALL", "summary": "45 Years and older" }, "enrollment_count": 10010, "start_date": "2010-07", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2016-08-25", "last_synced_at": "2026-09-16T15:27:46.435Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01082874" }, { "nct_id": "NCT02735707", "title": "Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Community-acquired Pneumonia, Influenza, COVID-19" ], "interventions": [ { "name": "Ceftriaxone", "type": "DRUG" }, { "name": "Moxifloxacin or Levofloxacin", "type": "DRUG" }, { "name": "Piperacillin-tazobactam", "type": "DRUG" }, { "name": "Ceftaroline", "type": "DRUG" }, { "name": "Amoxicillin-clavulanate", "type": "DRUG" }, { "name": "Standard course macrolide", "type": "DRUG" }, { "name": "Extended course macrolide", "type": "DRUG" }, { "name": "No systemic corticosteroid", "type": "OTHER" }, { "name": "Fixed-duration Hydrocortisone", "type": "DRUG" }, { "name": "Shock-dependent hydrocortisone", "type": "DRUG" }, { "name": "Fixed-duration higher dose Hydrocortisone", "type": "DRUG" }, { "name": "No antiviral agent for influenza", "type": "OTHER" }, { "name": "Five-days oseltamivir", "type": "DRUG" }, { "name": "Ten-days oseltamivir", "type": "DRUG" }, { "name": "No antiviral agent for COVID-19", "type": "OTHER" }, { "name": "Lopinavir / Ritonavir", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Hydroxychloroquine + lopinavir/ritonavir", "type": "DRUG" }, { "name": "Ivermectin", "type": "DRUG" }, { "name": "No immune modulation for COVID-19", "type": "OTHER" }, { "name": "Interferon beta-1a", "type": "DRUG" }, { "name": "Anakinra", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Sarilumab", "type": "DRUG" }, { "name": "Local standard venous thromboprophylaxis", "type": "DRUG" }, { "name": "Therapeutic dose anticoagulation", "type": "DRUG" }, { "name": "Conventional low dose thromboprophylaxis", "type": "DRUG" }, { "name": "Intermediate dose thromboprophylaxis", "type": "DRUG" }, { "name": "Continuation of therapeutic dose anticoagulation", "type": "DRUG" }, { "name": "No immunoglobulin", "type": "OTHER" }, { "name": "Convalescent plasma", "type": "BIOLOGICAL" }, { "name": "Delayed administration of convalescent plasma", "type": "BIOLOGICAL" }, { "name": "No vitamin C", "type": "OTHER" }, { "name": "Vitamin C", "type": "DRUG" }, { "name": "No antiplatelet", "type": "OTHER" }, { "name": "Aspirin", "type": "DRUG" }, { "name": "P2Y12 inhibitor", "type": "DRUG" }, { "name": "No simvastatin", "type": "OTHER" }, { "name": "Simvastatin", "type": "DRUG" }, { "name": "Eritoran", "type": "DRUG" }, { "name": "Apremilast", "type": "DRUG" }, { "name": "Clinician-preferred mechanical ventilation strategy", "type": "PROCEDURE" }, { "name": "Protocolised mechanical ventilation strategy", "type": "PROCEDURE" }, { "name": "No renin-angiotensin system inhibitor", "type": "OTHER" }, { "name": "Angiotensin converting enzyme inhibitor", "type": "DRUG" }, { "name": "Angiotensin Receptor Blockers", "type": "DRUG" }, { "name": "ARB + DMX-200", "type": "DRUG" }, { "name": "No cysteamine", "type": "OTHER" }, { "name": "Cysteamine", "type": "DRUG" }, { "name": "Fixed-duration dexamethasone", "type": "DRUG" }, { "name": "Baloxavir Marboxil", "type": "DRUG" }, { "name": "Five-days oseltamivir + baloxavir marboxil", "type": "DRUG" }, { "name": "Ten-days oseltamivir + baloxavir marboxil", "type": "DRUG" }, { "name": "No endothelial modulator", "type": "OTHER" }, { "name": "Imatinib", "type": "DRUG" }, { "name": "No Immune Modulator for Influenza", "type": "OTHER" }, { "name": "Baricitinib", "type": "DRUG" }, { "name": "Nirmatrelvir/ritonavir", "type": "DRUG" }, { "name": "Remdesivir", "type": "DRUG" }, { "name": "Nirmatrelvir/ritonavir + remdesivir", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "UMC Utrecht", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20000, "start_date": "2016-04-11", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2024-07-12", "last_synced_at": "2026-09-16T15:27:46.435Z", "location_count": 11, "location_summary": "Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02735707" }, { "nct_id": "NCT02556203", "title": "Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Transcatheter Aortic Valve Replacement" ], "interventions": [ { "name": "Rivaroxaban (Xarelto, BAY59-7939)", "type": "DRUG" }, { "name": "Acetylsalicylic Acid (ASA)", "type": "DRUG" }, { "name": "Clopidogrel", "type": "DRUG" }, { "name": "Vitamin K antagonist (VKA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1653, "start_date": "2015-12-16", "completion_date": "2018-11-27", "has_results": true, "last_update_posted_date": "2020-01-13", "last_synced_at": "2026-09-16T15:27:46.435Z", "location_count": 31, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Clearwater, Florida + 27 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02556203" }, { "nct_id": "NCT01259856", "title": "Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "High Risk Polycythemia Vera", "High Risk Essential Thrombocythemia" ], "interventions": [ { "name": "PEGASYS", "type": "DRUG" }, { "name": "Hydroxyurea", "type": "DRUG" }, { "name": "Aspirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ronald Hoffman", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 168, "start_date": "2011-09", "completion_date": "2017-06-30", "has_results": true, "last_update_posted_date": "2019-04-30", "last_synced_at": "2026-09-16T15:27:46.435Z", "location_count": 16, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 10 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01259856" }, { "nct_id": "NCT02227368", "title": "Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peripheral Artery Disease (PAD)" ], "interventions": [ { "name": "Ticagrelor", "type": "DRUG" }, { "name": "Comparator", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "50 Years to 130 Years" }, "enrollment_count": 40, "start_date": "2014-10-20", "completion_date": "2016-05-23", "has_results": true, "last_update_posted_date": "2017-07-19", "last_synced_at": "2026-09-16T15:27:46.435Z", "location_count": 10, "location_summary": "Daytona Beach, Florida • Jacksonville, Florida • Ocala, Florida + 7 more", "locations": [ { "city": "Daytona Beach", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Ocala", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Munster", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02227368" }, { "nct_id": "NCT01248468", "title": "Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pain, Migraine" ], "interventions": [ { "name": "Aspirin, acetaminophen and caffeine", "type": "DRUG" }, { "name": "Sumatriptan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 752, "start_date": "2010-11", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2012-07-30", "last_synced_at": "2026-09-16T15:27:46.435Z", "location_count": 20, "location_summary": "Anaheim, California • San Francisco, California • Clearwater, Florida + 17 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Clearwater", "state": "Florida" }, { "city": "DeLand", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01248468" }, { "nct_id": "NCT05625334", "title": "Study to Compare the Pharmacodynamics and Pharmacokinetics of Acetylsalicylic Acid Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Healthy Adults.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "ASA", "type": "DRUG" }, { "name": "non-enteric-coated chewable aspirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vectura, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 86, "start_date": "2022-10-14", "completion_date": "2023-03-09", "has_results": false, "last_update_posted_date": "2024-03-22", "last_synced_at": "2026-09-16T15:27:46.435Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Springfield, Missouri", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Springfield", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05625334" }, { "nct_id": "NCT04328883", "title": "Pharmacodynamics and Pharmacokinetics of Aspirin Inhalation Powder With Non-Enteric-Coated Chewable Aspirin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Platelet Aggregation Inhibitors" ], "interventions": [ { "name": "Aspirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inova Health Care Services", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 19, "start_date": "2019-07-16", "completion_date": "2019-10-10", "has_results": false, "last_update_posted_date": "2020-04-01", "last_synced_at": "2026-09-16T15:27:46.435Z", "location_count": 1, "location_summary": "Falls Church, Virginia", "locations": [ { "city": "Falls Church", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04328883" } ] }